Puma Biotechnology | PBYI - Коммерческие и административные расходы





Коммерческие и административные расходы Изменить Дата
Agios Pharmaceuticals USD 51.55M 13.09M 2026-06
Alnylam Pharmaceuticals USD 342M 5.92M 2026-09
Amgen USD 1.68B 40M 2026-09
Biogen USD 752M 42.3M 2026-09
BioMarin Pharmaceutical USD 333.64M 61.91M 2026-09
Daiichi Sankyo JPY 237.75B 12.21B 2026-09
Exelixis USD 154.56M 6.93M 2026-09
Gilead Sciences USD 1.52B 70M 2026-06
Glaxosmithkline GBP 2.38B 264M 2026-09
Incyte USD 364.27M 12.54M 2026-09
MacroGenics USD 7.9M 1.81M 2026-06
Moderna USD 282M 66M 2026-09
Novartis USD 3.08B 163M 2026-09
Pfizer USD 3.28B 132M 2026-09
PTC Therapeutics USD 80.63M 6.74M 2026-06
Puma Biotechnology USD 16.82M 8.15M 2024-09
Regeneron Pharmaceuticals USD 662.1M 14.4M 2026-06
Roche Holding CHF 6.37B 908M 2026-06
Sangamo BioSciences USD 9.64M 1.83M 2024-06
Sarepta Therapeutics USD 118.61M 11.01M 2026-09
Takeda JPY 271.71B 14.8B 2026-09
TG Therapeutics USD 62.32M 10.82M 2026-06
Ultragenyx Pharmaceutical USD 97M 9M 2026-09
Vanda Pharmaceuticals USD 39.28M 1.71M 2024-12
Vertex Pharmaceuticals USD 556.3M 25.9M 2026-09